Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives

被引：83

作者：

Rozeman, Elisa A. ^{[1
]}

Dekker, Tim J. A. ^{[1
]}

Haanen, John B. A. G. ^{[1
]}

Blank, Christian U. ^{[1
]}

机构：

[1] Netherlands Canc Inst, Dept Med Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

来源：

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY | 2018年 / 19卷 / 03期

关键词：

DABRAFENIB PLUS TRAMETINIB; METASTATIC UVEAL MELANOMA; TUMOR-INFILTRATING LYMPHOCYTES; BRAF-MUTANT MELANOMA; LONG-TERM SURVIVAL; OPEN-LABEL; CUTANEOUS MELANOMA; DOUBLE-BLIND; MALIGNANT-MELANOMA; COMBINED NIVOLUMAB;

D O I：

10.1007/s40257-017-0325-6

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Malignant melanoma accounts for the highest number of deaths from skin cancer, and the prognosis of patients with stage IV disease has historically been poor. Novel insights into both mutations driving tumorigenesis and immune escape mechanisms of these tumors have led to effective treatment options that have revolutionized the treatment of this disease. Targeting the MAPK kinase pathway (with BRAF and MEK inhibitors), as well as targeting checkpoints, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or programmed death 1 (PD-1), have improved overall survival in patients with late-stage melanoma, and biomarker research for personalized therapy is ongoing for each of these treatment modalities. In this review, we will discuss current first-line treatment options, discuss biomarkers supporting treatment decisions, and give an outlook on (combination) therapies we expect to become relevant in the near future.

引用

页码：303 / 317

页数：15

共 143 条

[41] Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) plus trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. [J].

Flaherty, Keith ;

Davies, Michael A. ;

Grob, Jean Jacques ;

Long, Georgina V. ;

Nathan, Paul D. ;

Ribas, Antoni ;

Robert, Caroline ;

Schadendorf, Dirk ;

Frederick, Dennie T. ;

Hammond, Marc R. ;

Jane-Valbuena, Judit ;

Mu, Xinmeng Jasmine ;

Squires, Matthew ;

Jaeger, Savina A. ;

Lane, Stephen R. ;

Mookerjee, Bijoyesh ;

Garraway, Levi A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[42] BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma [J].

Frederick, Dennie T. ;

Piris, Adriano ;

Cogdill, Alexandria P. ;

Cooper, Zachary A. ;

Lezcano, Cecilia ;

Ferrone, Cristina R. ;

Mitra, Devarati ;

Boni, Andrea ;

Newton, Lindsay P. ;

Liu, Chengwen ;

Peng, Weiyi ;

Sullivan, Ryan J. ;

Lawrence, Donald P. ;

Hodi, F. Stephen ;

Overwijk, Willem W. ;

Lizee, Gregory ;

Murphy, George F. ;

Hwu, Patrick ;

Flaherty, Keith T. ;

Fisher, David E. ;

Wargo, Jennifer A. .

CLINICAL CANCER RESEARCH, 2013, 19 (05) :1225-1231

[43] Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma [J].

Furney, Simon J. ;

Turajlic, Samra ;

Stamp, Gordon ;

Nohadani, Mahrokh ;

Carlisle, Anna ;

Thomas, J. Meirion ;

Hayes, Andrew ;

Strauss, Dirk ;

Gore, Martin ;

van den Oord, Joost ;

Larkin, James ;

Marais, Richard .

JOURNAL OF PATHOLOGY, 2013, 230 (03) :261-269

[44] Overall Survival and PD-L1 Expression in Metastasized Malignant Melanoma [J].

Gadiot, Jules ;

Hooijkaas, Anna I. ;

Kaiser, Andrew D. M. ;

van Tinteren, Harm ;

van Boven, Hester ;

Blank, Christian .

CANCER, 2011, 117 (10) :2192-2201

[45] Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037 [J].

Gangadhar, T. C. ;

Hamid, O. ;

Smith, D. C. ;

Bauer, T. M. ;

Wasser, J. S. ;

Olszanski, A. J. ;

Luke, J. J. ;

Balmanoukian, A. S. ;

Kaufman, D. R. ;

Zhao, Y. ;

Maleski, J. ;

Jones, M. J. ;

Leopold, L. ;

Gajewski, T. F. .

ANNALS OF ONCOLOGY, 2016, 27

[46] Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects [J].

Garbe, Claus ;

Eigentler, Thomas K. ;

Keilholz, Ulrich ;

Hauschild, Axel ;

Kirkwood, John M. .

ONCOLOGIST, 2011, 16 (01) :5-24

[47] Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial [J].

Goldberg, Sarah B. ;

Gettinger, Scott N. ;

Mahajan, Amit ;

Chiang, Anne C. ;

Herbst, Roy S. ;

Sznol, Mario ;

Tsiouris, Apostolos John ;

Cohen, Justine ;

Vortmeyer, Alexander ;

Jilaveanu, Lucia ;

Yu, James ;

Hegde, Upendra ;

Speaker, Stephanie ;

Madura, Matthew ;

Ralabate, Amanda ;

Rivera, Angel ;

Rowen, Elin ;

Gerrish, Heather ;

Yao, Xiaopan ;

Chiang, Veronica ;

Kluger, Harriet M. .

LANCET ONCOLOGY, 2016, 17 (07) :976-983

[48] Population-Based 20-Year Survival Among People Diagnosed With Thin Melanomas in Queensland, Australia [J].

Green, Adele C. ;

Baade, Peter ;

Coory, Michael ;

Aitken, Joanne F. ;

Smithers, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) :1462-1467

[49] Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer A Systematic Review of the Literature [J].

Guy, Gery P., Jr. ;

Ekwueme, Donatus U. .

PHARMACOECONOMICS, 2011, 29 (10) :863-874

[50]

Haarberg H Eirik, 2014, Drug Discov Today Technol, V11, P27, DOI 10.1016/j.ddtec.2013.12.004

← 1 2 3 4 5 6 7 8 9 10 →